Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 7357495, 9 pages
https://doi.org/10.1155/2017/7357495
Research Article

Heparanase Inhibition Reduces Glucose Levels, Blood Pressure, and Oxidative Stress in Apolipoprotein E Knockout Mice

1Internal Medicine E Department, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel
2Internal Medicine A Department, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel
3Lipid Research Laboratory, Rappaport Faculty of Medicine, Technion, Haifa, Israel
4Pathology Department, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel

Correspondence should be addressed to Shadi Hamoud; li.vog.htlaeh.mabmar@duomah_s

Received 30 April 2017; Revised 7 August 2017; Accepted 17 September 2017; Published 26 October 2017

Academic Editor: Sivagnanam Thamilselvan

Copyright © 2017 Shadi Hamoud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Atherosclerosis is a multifactorial process. Emerging evidence highlights a role of the enzyme heparanase in various disease states, including atherosclerosis formation and progression. Objective. The aim of the study was to investigate the effect of heparanase inhibition on blood pressure, blood glucose levels, and oxidative stress in apoE−/− mice. Methods. Male apoE−/− mice were divided into two groups: one treated by the heparanase inhibitor PG545, administered intraperitoneally weekly for seven weeks, and the other serving as control group (injected with saline). Blood pressure was measured a day before sacrificing the animals. Serum glucose levels and lipid profile were measured. Assessment of oxidative stress was performed as well. Results. PG545 significantly lowered blood pressure and serum glucose levels in treated mice. It also caused significant reduction of the serum oxidative stress. For safety concerns, liver enzymes were assessed, and PG545 caused significant elevation only of alanine aminotransferase, but not of the other hepatic enzymes. Conclusion. Heparanase inhibition by PG545 caused marked reduction of blood pressure, serum glucose levels, and oxidative stress in apolipoprotein E deficient mice, possibly via direct favorable metabolic and hemodynamic changes caused by the inhibitor. Possible hepatotoxic and weight wasting effects are subject for future investigation.